Immunotherapy Pembrolizumab Works Better Than Chemotherapy Alone as Initial Treatment for Most Advanced Lung Cancers

For immediate release
June 3, 2018

MEDIA CONTACT:
Alise Fisher
571-483-1354
alise.fisher@asco.org

PATIENT AND CAREGIVER INQUIRIES:
Contact Cancer.Net

 

ASCO Perspective
“Immunotherapy with pembrolizumab alone benefits a much larger number of patients than we had previously thought. This is yet another promising result with immunotherapy in lung cancer that brings new momentum to the treatment of this notoriously difficult disease,” said ASCO Expert John Heymach, MD, PhD.

CHICAGO – A large, randomized phase III trial shows that the immunotherapy pembrolizumab (Keytruda®) is a more effective initial treatment than chemotherapy (the current standard of care) for the majority of patients with the most common type of lung cancer. People with advanced non-small-cell lung cancer (NSCLC) with a PD-L1 expression of 1% or more who were first treated with immunotherapy pembrolizumab lived a median of 4-8 months longer than those who received chemotherapy. In addition, severe side effects occurred in fewer patients receiving pembrolizumab than chemotherapy (18% vs. 41%).

According to the authors, this study (KEYNOTE-042) is the largest clinical trial of pembrolizumab as a standalone therapy. The findings will be presented in ASCO’s Plenary Session, which features four studies deemed to have the greatest potential impact on patient care, out of the more than 5,800 abstracts featured as part of the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.

“A large number of patients with lung cancer now have a new treatment option with better efficacy and fewer side effects than standard chemotherapy,” said lead study author Gilberto Lopes, MD, MBA, a medical oncologist at the Sylvester Comprehensive Cancer Center, University of Miami Health System in Florida. “Our study shows that pembrolizumab provides more benefit than chemotherapy for two-thirds of all people with the most common type of lung cancer.”

Based on findings from a previous, smaller clinical trial (KEYNOTE-024), the U.S. Food and Drug Administration (FDA) approved pembrolizumab for initial treatment of NSCLC with high PD-L1 expression (score of at least 50%), which account for about one-third of these cancers. Pembrolizumab is currently the only approved immunotherapy for initial treatment of lung cancer. It is approved for use as a standalone treatment and in combination with chemotherapy.

PD-L1 is a biomarker commonly used to predict response to immune checkpoint inhibitors, including pembrolizumab. Generally, tumors with more PD-L1 (high expression) respond better to these treatments, but in some studies, these immunotherapies were effective even against tumors with little or no detectable PD-L1. In prior trials of second-line therapy for NSCLC, pembrolizumab was effective in treating tumors with PD-L1 expression of at least 1%.

About the Study
Researchers randomly assigned 1,274 people with locally advanced or metastatic NSCLC to receive chemotherapy (paclitaxel plus carboplatin or pemetrexed plus carboplatin) or pembrolizumab. Both squamous and non-squamous cancers were included, but not cancers with genetic changes that can be treated with targeted therapies (EGFR and ALK inhibitors).

For the analysis, researchers explored treatment benefits in three patient groups according to tumor PD-L1 expression score: at least 50% (599 patients), at least 20% (818 patients), and at least 1% (1,274 patients). Equal numbers of patients in each PD-L1 expression group received pembrolizumab and chemotherapy.

Key Findings
The median follow-up time was 12.8 months. Compared to those receiving standard chemotherapy, patients who received pembrolizumab had a longer median overall survival, regardless of PD-L1 expression in the tumor. The benefit of pembrolizumab was greater when the level of PD-L1 expression was higher:

  • PD-L1 50% or more: 20 months with pembrolizumab vs. 12.2 months with chemotherapy 
  • PD-L1 20% or more: 17.7 months with pembrolizumab vs. 13 months with chemotherapy
  • PD-L1 1% or more: 16.7 months with pembrolizumab vs. 12.1 months with chemotherapy

Next Steps
More research is needed to define patient groups who benefit from pembrolizumab. The three broad groupings by PD-L1 expression in the current analysis do not allow researchers to predict the benefit from pembrolizumab for patients with a specific PD-L1 expression level.

Additionally, it is not yet clear whether pembrolizumab combined with chemotherapy is better than pembrolizumab alone in patients who express PD-L1, as there have not been head-to-head comparison trials of the two approaches.

Ongoing research is also exploring use of pembrolizumab after surgery (adjuvant) and combinations of immunotherapy with bevacizumab-containing combination regimens as part of initial therapy for NSCLC.

This study received funding from Merck.

Study at a Glance

Disease

Advanced non-small-cell lung cancer 

Trial Phase, Type

Phase III, randomized

Patients on Trial

1,274

Intervention Tested

Pembrolizumab vs. chemotherapy

Primary Finding

For most patients with advanced NSCLC, initial treatment with pembrolizumab prolongs survival compared to chemotherapy.

 

View the full abstract.

For your readers:

View the disclosures for the 2018 ASCO Annual Meeting News Planning Team.

ATTRIBUTION TO THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING IS REQUESTED IN ALL COVERAGE.

###

About ASCO: 

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents nearly 45,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at www.ASCO.org, explore patient education resources at www.Cancer.Net, and follow us on Facebook, Twitter, LinkedIn, and YouTube.